Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECHARGE-1
NCT06799000Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of remibrutinib in hidradenitis suppurativa (HS), sponsored by Novartis. Started Jan 2025; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06799000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799000.